Loading...
Please wait, while we are loading the content...
Similar Documents
Chemical Information Review Document for Evening Primrose Oil ( Oenothera biennis L . ) [ CAS No . 90028-66-3 ]
| Content Provider | Semantic Scholar |
|---|---|
| Copyright Year | 2009 |
| Abstract | Evening primrose oil (EPO) has been used to treat a variety of ailments including PMS, atopic eczema, psoriasis, multiple sclerosis, cancer, coronary heart disease, diabetic neuropathy, autoimmune conditions, and gastrointestinal symptoms. It is classified as a "dietary supplement" under the Dietary Supplement Health and Education Act of 1994. Overall, the data on the efficacy of EPO for treating the various diseases indicated is limited and EPO appears to have little toxicological effect in humans. Some side effects from the use of EPO have been reported including occasional headache, abdominal pain, nausea, loose stools and seizures. The mouse LD50 reported in a single acute toxicity study was 3.12×10 μg/kg. Subchronic and chronic studies indicated that EPO produced few toxicological effects. EPO, given in the diet starting three weeks after dimethylbenz(a)anthracene treatment, had no effect on mammary tumor incidence in female Sprague-Dawley rats but did reduce the number of tumors per rat and increased the tumor latency period. EPO also inhibited the promotion stages of skin papilloma development. In vivo studies showed that EPO blocked benzo(a)pyrene (BaP)-induced micronuclei in murine bone marrow cells and BaP binding to murine skin cell DNA. It is cytotoxic to a variety of cell types (e.g., human and mouse leukemic cell lines and Ehrlich ascites tumor cells). In one study, EPO enhanced male reproductive function in ICR mice (e.g., number of successful copulations during a three-hour period, the number of sperm-positive females) but had no effect on female reproduction in Wistar rats. Results from studies of EPO's carcinogenic effects were conflicting; EPO increased the mean tumor mass in C57 mice transplanted with BL6 melanoma cells but had no effect on either tumor growth in mice that had murine sarcoma allografts or tumor incidence in CD-1 mice. Additional activities of EPO included immunomodulatory, cardiovascular, enzyme, endocrine, and antibacterial, antifungal, and antioxidant effects. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://ntp.niehs.nih.gov/ntp/noms/support_docs/evening_primrose_nov2009.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
